This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Prevention of Sars-Cov-2 Transmission During a Large, Live, Indoor Gathering: The Noninferiority Randomised-Controlled Spring Trial (preprint)
ssrn; 2021.
Preprint
in English
| PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.3905915
ABSTRACT
Background:
Mass indoor gatherings were banned in early 2020 to prevent SARS-CoV-2 spread. We aimed to assess, under controlled conditions, whether systematic antigen-screening within 3 days, medical mask-wearing and optimized ventilation could prevent SARS-CoV-2 spread during a large, indoor gathering without physical distancing.Methods:
The non-inferiority, prospective, open-label, randomized (21)-controlled SPRING trial was conducted on May 29, 2021 in Paris, France. Participants, 18–45 years old, had no comorbidities, COVID-19 symptoms and recent case contact, and a negative rapid antigen diagnostic test within 3 days before the concert. Participants were randomly allocated to the experimental arm (attendees) or to the control arm (non-attendees). The primary outcome measure was the number of SARS-CoV-2–positive RT-PCR on self-collected saliva 7 days (D7) post-gathering. An artificial intelligence tool analyzing anonymised, continuous video-capture data evaluated participants’ mask-wearing compliance. This trial is registered with ClinicalTrials.gov, NCT04872075.Findings:
Among 6678 randomized participants (median age 28 years; 59% women), 88% of each group complied with follow-up requirements. The D7 RT-PCR was positive for eight of the 3917 attendees (observed incidence, 0.20%; 95% Confidence Interval [CI], 0.09 to 0.40) and 3 of the 1,947 non-attendees (0.15%; 0.03 to 0.45) (absolute difference, 95%CI, –0.26% to +0.28%), findings that met the non-inferiority criterion (margin <0.35%) for the primary endpoint. Global facemask-wearing compliance (i.e., covering nose and mouth) was estimated at 91.4% (95%CI, 87.7 to 95.4).Interpretation:
Participation in a large, indoor, live gathering without physical distancing was not associated with increased SARS-CoV-2–transmission risk, provided a comprehensive preventive intervention was implemented.Trial Registration This study was registered on ClinicalTrials.gov (NCT04872075).Funding:
French Ministry of HealthDeclaration of Interest All authors declare no competing interestsEthical Approval The trial protocol was approved by the Scientific Ethics Committee of the Sud-Ouest and Outremer Regions of France and the French Data-Protection Agency
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-SSRN
Main subject:
COVID-19
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS